Company Overview of Ovamed GmbH
Ovamed GmbH specializes in the development of treatments using biological organisms. It owns license to produce and commercialize Helminthic therapy, a biological approach to treat autoimmune diseases, such as Crohn`s disease and Ulcerative colitis. The company was formerly known as Biocure GmbH and changed its name to Ovamed GmbH in 2004. Ovamed GmbH was founded in 2003 and is based in Barsbüttel, Germany.
Founded in 2003
Key Executives for Ovamed GmbH
Managing Director of Finance and Administration
Managing Director and Partner
Head of Production and Partner
Compensation as of Fiscal Year 2013.
Ovamed GmbH Key Developments
Coronado Biosciences, Inc. Acquires TSO Manufacturing Rights from Ovamed GmbH
Dec 27 12
Coronado Biosciences Inc. announced the acquisition of manufacturing rights to its lead product TSO (Trichuris suis ova or CNDO-201) from Ovamed GmbH, for North America, South America, and Japan, Coronado's licensed territory. As part of the transaction, Coronado entered into a lease agreement to establish a manufacturing facility in Woburn, MA to produce TSO. Coronado entered into amendments to its existing license and supply agreements with Ovamed expanding Coronado's exclusive license to include TSO manufacturing rights in Coronado's territory and terminating Ovamed's exclusive supply rights once Coronado's planned manufacturing facility is operational. Build out and site preparation of the manufacturing facility are planned to commence in early 2013 and continue throughout the year to enable production of phase 3 supplies of TSO. Ovamed agreed to provide assistance in establishing the manufacturing facility and to continue to supply Coronado with clinical supplies until the facility is operational. Ovamed retains TSO manufacturing rights outside Coronado's territory, and the amendments contemplate that Coronado and Ovamed would act as second source suppliers to each other at agreed transfer prices. Under the amendments, Coronado will pay Ovamed a total of $1.5 million in three equal installments in 2014-2016, and, in lieu of product supply payments that would have been payable to Ovamed as the exclusive supplier, certain fees for product manufactured and sold by Coronado.
Coronado Biosciences, Inc. Signs Collaboration Agreement with Dr. Falk Pharma GmbH and Ovamed GmbH for the Development of TSO for Crohn's Disease
Mar 22 12
Coronado Biosciences, Inc. announced that the company signed a Collaboration Agreement with Dr. Falk Pharma GmbH and Ovamed GmbH the development of TSO (Trichuris suis ova or CNDO-201) for Crohn's disease. On December 22, 2011, Coronado announced the execution of a binding Terms of Agreement with respect to this collaboration. Under the Collaboration Agreement, Falk granted Coronado exclusive rights and licenses under certain Falk patent rights, pre-clinical data and clinical data from Falk's clinical trials of TSO in Crohn's disease, including an ongoing Phase 2 clinical trial, for use in North America, South America and Japan. Coronado granted Falk exclusive rights and licenses to data from Coronado's clinical trials of TSO in Crohn's disease for use in Europe. Under the agreement, Coronado agreed to pay Falk a total of EUR 5 million after receipt of certain pre-clinical and clinical data, all of which is estimated to be paid within 12 months, and a royalty of 1% of net sales of TSO.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|